Viral infections as a cause of cancer (review).

In order to promote carcinogenesis multiple factors must be orchestrated. The alteration of the cellular genome after a carcinogenic exposure may result in malignancy if apoptosis is prevented and the immune surveillance fails to eliminate the transformed cell. Infectious agents may exert these properties and transform a host cell. Viruses associated with human cancer are known as 'tumor viruses'. Most of them are capable of integrating into the host genome and have the ability to immortalize the target cell in order to allow their own replication. The infected cell expresses the viral genes, which are able to induce cell growth, proliferation and prevent apoptosis. This review focuses on Epstein-Barr virus, human papilloma virus, hepatitis C virus, hepatitis B virus, human herpes virus 8 and human T-cell leukemia virus, since they have been already established as causative agents of human cancer. An understanding of the viral replication mechanism may provide new targets for the development of specified viral therapy that may have an impact not only on viral infections but in human cancer as well.

[1]  A. Giordano,et al.  From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells , 2007, Journal of cellular physiology.

[2]  A. Giordano,et al.  Multidisciplinary international conference on gynecologic cancer, Bologna, Italy, June 8–12, 2005 , 2006, Journal of cellular physiology.

[3]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[4]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[5]  A. Batistatou,et al.  Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. , 2005, Journal of experimental & clinical cancer research : CR.

[6]  E. Palescandolo,et al.  Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells , 2005, Journal of cellular physiology.

[7]  K. Jeang,et al.  Molecular mechanisms of cellular transformation by HTLV-1 Tax , 2005, Oncogene.

[8]  L. Coussens,et al.  The interplay between innate and adaptive immunity regulates cancer development , 2005, Cancer Immunology, Immunotherapy.

[9]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[10]  J. Burger,et al.  KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway , 2005, Oncogene.

[11]  H. Bernard.  The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses , 2005, Journal of Clinical Virology.

[12]  D. Wolf,et al.  KAPOSI'S SARCOMA–ASSOCIATED HERPESVIRUS: Clinical, Diagnostic, and Epidemiological Aspects , 2005, Critical reviews in clinical laboratory sciences.

[13]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[14]  S. Sakaguchi,et al.  CD4+ Tregs and immune control. , 2004, The Journal of clinical investigation.

[15]  K. Mills,et al.  Regulatory T cells: friend or foe in immunity to infection? , 2004, Nature Reviews Immunology.

[16]  M. Ebell.  Epstein-Barr virus infectious mononucleosis. , 2004, American family physician.

[17]  B. Rouse,et al.  CD4+CD25+ Regulatory T Cells Control the Severity of Viral Immunoinflammatory Lesions1 , 2004, The Journal of Immunology.

[18]  S. Kashiwagi,et al.  A decrease in mother-to-child transmission of human T lymphotropic virus type I (HTLV-I) in Okinawa, Japan. , 2004, The American journal of tropical medicine and hygiene.

[19]  E. Golemis,et al.  Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation. , 2003, Cancer research.

[20]  C. Cinti,et al.  How does a normal human cell become a cancer cell? , 2003, Journal of experimental & clinical cancer research : CR.

[21]  M. Matsuda,et al.  Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis , 2003, International journal of cancer.

[22]  Masao Matsuoka,et al.  Human T-cell leukemia virus type I and adult T-cell leukemia , 2003, Oncogene.

[23]  Yoshiki Murakami,et al.  Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene , 2003, Oncogene.

[24]  E. Harhaj,et al.  Characterization of a Nuclear Export Signal within the Human T Cell Leukemia Virus Type I Transactivator Protein Tax* , 2003, Journal of Biological Chemistry.

[25]  C. Harris,et al.  Nitric oxide in cancer and chemoprevention. , 2003, Free radical biology & medicine.

[26]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[27]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[28]  K. Jeang,et al.  Physical Interaction of Human T-Cell Leukemia Virus Type 1 Tax with Cyclin-Dependent Kinase 4 Stimulates the Phosphorylation of Retinoblastoma Protein , 2002, Molecular and Cellular Biology.

[29]  Philipp Lirk,et al.  Inducible nitric oxide synthase--time for reappraisal. , 2002, Current drug targets. Inflammation and allergy.

[30]  M. Reitz,et al.  Activation of NF-κB by the Human Herpesvirus 8 Chemokine Receptor ORF74: Evidence for a Paracrine Model of Kaposi's Sarcoma Pathogenesis , 2001, Journal of Virology.

[31]  S. Do,et al.  The Hepatitis B Virus-X Protein Activates a Phosphatidylinositol 3-Kinase-dependent Survival Signaling Cascade* , 2001, The Journal of Biological Chemistry.

[32]  J. Woodgett,et al.  X Protein of Hepatitis B Virus Inhibits Fas-mediated Apoptosis and Is Associated with Up-regulation of the SAPK/JNK Pathway* , 2001, The Journal of Biological Chemistry.

[33]  C. Sample,et al.  Epstein-Barr Virus Nuclear Antigen 3C Activates the Latent Membrane Protein 1 Promoter in the Presence of Epstein-Barr Virus Nuclear Antigen 2 through Sequences Encompassing an Spi-1/Spi-B Binding Site , 2000, Journal of Virology.

[34]  P. Howley,et al.  Repression of the Integrated Papillomavirus E6/E7 Promoter Is Required for Growth Suppression of Cervical Cancer Cells , 2000, Journal of Virology.

[35]  J. Hauw,et al.  Overexpression of BCL-2, BCL-X, and BAX in Primary Central Nervous System Lymphomas that Occur in Immunosuppressed Patients , 2000, Modern Pathology.

[36]  J. Parsonnet.  Microbes and malignancy : infection as a cause of human cancers , 1999 .

[37]  R. Purcell,et al.  Quasispecies in viral persistence and pathogenesis of hepatitis C virus. , 1999, Trends in microbiology.

[38]  V. Tergaonkar,et al.  Pleiotropic effects of human papillomavirus type 16 E6 oncogene expression in human epithelial cell lines. , 1999, The Journal of general virology.

[39]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins , 1999, The EMBO journal.

[40]  M. Ballestas,et al.  Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. , 1999, Science.

[41]  E. van Marck,et al.  Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Valerie Beral,et al.  Human immunodeficiency virus infection and cancer , 1998 .

[43]  Y. Yun,et al.  HBx Protein of Hepatitis B Virus Activates Jak1-STAT Signaling* , 1998, The Journal of Biological Chemistry.

[44]  N. Dyson.  The regulation of E2F by pRB-family proteins. , 1998, Genes & development.

[45]  T. Schulz,et al.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). , 1998, The Journal of general virology.

[46]  D. Liebowitz.  Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. , 1998, The New England journal of medicine.

[47]  L. Young,et al.  Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) , 1998, Oncogene.

[48]  V. Beral,et al.  Overview of the epidemiology of immunodeficiency-associated cancers. , 1998, Journal of the National Cancer Institute. Monographs.

[49]  C. Szabó,et al.  DNA damage induced by peroxynitrite: subsequent biological effects. , 1997, Nitric oxide : biology and chemistry.

[50]  L. Young,et al.  Epstein – Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors , 1997, Oncogene.

[51]  J. Chen,et al.  The role of Epstein-Barr virus in lymphoid malignancies. , 1997, Critical reviews in oncology/hematology.

[52]  E. Cheng,et al.  A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  V. Diehl,et al.  [Hodgkin's disease]. , 1996, Revue medicale suisse.

[54]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[55]  A. Levine,et al.  Expression of Epstein‐Barr virus nuclear antigen‐1 induces B cell neoplasia in transgenic mice. , 1996, The EMBO journal.

[56]  D. Baltimore,et al.  TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation. , 1996, Genes & development.

[57]  J. McDougall,et al.  Telomerase activation by the E6 gene product of human papillomavirus type 16 , 1996, Nature.

[58]  Stefan Imreh,et al.  Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1 , 1995, Nature.

[59]  C. Ware,et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.

[60]  J. Yokota,et al.  Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  H. Cen,et al.  Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. , 1993, Blood.

[62]  Carol D. Laherty,et al.  The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. , 1992, The Journal of biological chemistry.

[63]  S. Tabata,et al.  Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[64]  T. Sugimura,et al.  Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product , 1991, Journal of Virology.

[65]  A. Dalgleish,et al.  Kaposi's sarcoma. , 1991, British Journal of Cancer.

[66]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.

[67]  Gwyn T. Williams,et al.  Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis , 1991, Nature.

[68]  T. Hunter.  Cooperation between oncogenes , 1991, Cell.

[69]  G. Lenoir,et al.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene , 1991, Journal of virology.

[70]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[71]  A. Evans,et al.  Viruses and cancer. Causal associations. , 1990, Annals of epidemiology.

[72]  T. Tokino,et al.  Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. , 1990, Molecular biology & medicine.

[73]  M. Rowe,et al.  Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein , 1990, Journal of virology.

[74]  C. Meyers,et al.  The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties , 1990, Journal of virology.

[75]  R C Gallo,et al.  The first human retrovirus. , 1986, Scientific American.

[76]  K. Grzeschik,et al.  Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma , 1986, Nature.

[77]  P. Lazo.  Pathogenesis of viral infections. , 1985, The New England journal of medicine.

[78]  N. Raab-Traub,et al.  Epstein-Barr virus replication in oropharyngeal epithelial cells. , 1984, The New England journal of medicine.

[79]  G. Steele.  Cancer: Principles and Practice of Oncology , 1983 .

[80]  J. Butel,et al.  Cell transformation by viruses , 1971, In Vitro.

[81]  R. Dulbecco.  Cell transformation by viruses. , 1969, Science.

[82]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[83]  John McGrath,et al.  Hodgkin’s Disease , 1933, JAMA.

[84]  S. Ferrone,et al.  Mechanisms of tumor evasion. , 2005, Cancer treatment and research.

[85]  J. Beebe-Dimmer,et al.  Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. , 2005, Annual review of public health.

[86]  M. Matsuda,et al.  ALTERATIONS OF RB 1 , p 53 AND Wnt PATHWAYS IN HEPATOCELLULAR CARCINOMAS ASSOCIATED WITH HEPATITIS C , HEPATITIS B AND ALCOHOLIC LIVER CIRRHOSIS , 2003 .

[87]  L. Laimins,et al.  Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation , 2003, Oncogene.

[88]  J. Bruix,et al.  Hepatitis B virus and hepatocellular carcinoma. , 2003, Journal of hepatology.

[89]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[90]  D. Jeannel,et al.  Nasopharyngeal carcinoma : An epidemiological approach to carcinogenesis , 1999 .

[91]  L. Brooks,et al.  Epstein-Barr virus and lymphomas , 1999 .

[92]  R. Ambinder,et al.  Epstein-Barr virus and lymphoma. , 1999, Cancer treatment and research.

[93]  Ch Lai,et al.  Virocrine transformation: the intersection between viral transforming proteins and cellular signal transduction pathways. , 1998, Annual review of microbiology.

[94]  C. Bréchot.  Hepatitis C virus: molecular biology and genetic variability. , 1996, Digestive diseases and sciences.

[95]  G. Natoli,et al.  Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX. , 1995, Journal of hepatology.

[96]  M. Buendia.  Hepatitis B viruses and hepatocellular carcinoma. , 1992, Advances in cancer research.

[97]  B. Slagle,et al.  Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. , 1991, Cancer research.

[98]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[99]  H. Towler,et al.  Adult T-cell leukemia : antigen in an ATL cell line and detection of antibodies to the antigen in human sera , 2022 .